This study provided more evidence to support the view that the therapeutic schedule of extended adjuvant TMZ significantly prolonged OS and PFS of patients with newly diagnosed GBM regardless of p53 mutation status, and patients with IDH1 mutation were more suitable for this treatment. Here, IDH1 is linked to glioblastoma.